Label (71610 0922 45)
Rosuvastatin Tablet, Film Coated
Product Images NDC 71610-922
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rosuvastatin (NDC 71610-922). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aphena (Aphena)
Figure-01 (Figure 1)
Figure-02 (Figure 2)
The extracted data provides information on the number of events and corresponding outcomes for a study involving Rosuva 20 mg and Placebo 20 mg. It includes details on primary endpoints (MCE), cardiovascular death, nonfatal stroke, nonfatal MI, hospitalized unstable angina, and arterial revascularization. The hazard ratios with confidence intervals and p-values are also given for each endpoint, showing the comparison between the two treatments. The study includes a sample size of 8901 participants and provides insights into the effectiveness of Rosuva 20 mg compared to placebo in reducing cardiovascular events.*
Figure-02 (Figure 3)
Structural Formula (Rosuvastatin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
